Palleon Pharmaceuticals to Present on Cancer Drug Development

Biotech company to share updates on HLX316/E-688 at AACR conference.

Apr. 2, 2026 at 2:28pm

Got story updates? Submit your updates here. ›

A highly detailed, ghostly X-ray image revealing the complex internal structure of a cancer cell, conceptually illustrating the innovative research Palleon Pharmaceuticals is conducting to develop new treatments.Palleon Pharmaceuticals' presentation at the AACR conference will highlight its progress in developing a novel cancer immunotherapy that targets the molecular mechanisms underlying tumor growth.Waltham Today

Palleon Pharmaceuticals, a biotechnology company based in Waltham, Massachusetts, announced that it will present on the development of its cancer drug candidate HLX316/E-688 at the upcoming American Association for Cancer Research (AACR) annual meeting.

Why it matters

As a leading biotech hub, developments in cancer research and drug pipelines from companies like Palleon are closely watched by the medical community and investors. Presentations at major conferences like AACR provide an important platform for biotech firms to share progress on promising new therapies.

The details

Palleon Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel immunotherapies to treat cancer. The company will present updates on the preclinical and clinical development of its lead drug candidate HLX316/E-688, which is designed to target glycan-mediated immune suppression in solid tumors.

  • The AACR annual meeting is scheduled for April 12-17, 2026.

The players

Palleon Pharmaceuticals

A clinical-stage biotechnology company based in Waltham, Massachusetts that is developing novel cancer immunotherapies.

HLX316/E-688

Palleon's lead drug candidate designed to target glycan-mediated immune suppression in solid tumors.

American Association for Cancer Research (AACR)

A leading professional organization for cancer researchers that hosts an annual scientific conference.

Got photos? Submit your photos here. ›

What’s next

Palleon's presentation at the AACR conference will provide the latest updates on the preclinical and clinical development of HLX316/E-688, which could signal progress towards potential regulatory filings and future clinical trials.

The takeaway

As a prominent biotech hub, developments from Waltham-based Palleon Pharmaceuticals on its cancer drug pipeline are closely watched by the medical and investment communities. The company's upcoming presentation at the AACR conference will be an important milestone in sharing its progress on innovative immunotherapy approaches.